[
    {
        "question": "Fuse micro-CT evidence of early terminal bronchiole loss with PRM subtyping (PRMfSAD vs PRMemph) and GOLD’s ABCD follow-up rules to design a stepwise pathway for symptomatic smokers who have normal spirometry today. Specify what imaging and labs you order now, the first maintenance regimen you would choose if obstruction later appears, and the exact follow-up intervals you schedule.",
        "answer": "Micro-CT shows terminal and transitional bronchioles are already destroyed in mild COPD and even before emphysema is measurable, with losses of about 41% in GOLD 1, 43% in GOLD 2, and 69% in GOLD 4 lungs, indicating small-airway disease precedes emphysema.  [oai_citation:0‡copd1.pdf](file-service://file-Jp9Dg7PFwwroaWrY9gN43h) PRM distinguishes non-emphysematous gas trapping (PRMfSAD) from true emphysema (PRMemph) and PRMfSAD tracks early disease, faster FEV1 decline, and future emphysema development; add PRM to inspiratory/expiratory CT to phenotype risk now.  [oai_citation:1‡copd1.pdf](file-service://file-Jp9Dg7PFwwroaWrY9gN43h) If airflow limitation later meets COPD criteria, apply GOLD ABCD to select therapy and prefer dual bronchodilation (LAMA/LABA) initially for symptomatic patients while reserving ICS escalation for biomarker-supported exacerbation risk.  [oai_citation:2‡copd2.pdf](file-service://file-J3qMYmVkVT92PhaYshQrtt) Schedule targeted surveillance in the high-risk post-event windows (1–4 weeks and 12–16 weeks after any exacerbation) and annual re-imaging only if it would change management.  [oai_citation:3‡copd2.pdf](file-service://file-J3qMYmVkVT92PhaYshQrtt)"
    },
    {
        "question": "Create an escalation algorithm that integrates eosinophil thresholds for ICS benefit with PRMfSAD predominance and last-year exacerbation count. Define when you would keep LAMA/LABA, when you would add ICS (triple therapy), and when you would choose roflumilast or azithromycin instead.",
        "answer": "Use prior-year exacerbations as the strongest predictor of future events and verify technique/adherence before any change.  [oai_citation:4‡copd2.pdf](file-service://file-J3qMYmVkVT92PhaYshQrtt) If exacerbations persist on LAMA/LABA and eosinophils are ≥100 cells/µL, escalate to triple therapy; if eosinophils are <100 cells/µL with chronic bronchitis and FEV1 <50%, add roflumilast; in former smokers with recurrent events and low eosinophils, consider azithromycin.  [oai_citation:5‡copd2.pdf](file-service://file-J3qMYmVkVT92PhaYshQrtt) Weigh PRMfSAD burden as an early-disease driver of decline to justify earlier initiation or continuation of dual bronchodilation while deferring ICS if biomarkers do not suggest benefit.  [oai_citation:6‡copd1.pdf](file-service://file-Jp9Dg7PFwwroaWrY9gN43h)"
    },
    {
        "question": "Draft an inpatient steroid policy for AECOPD that reconciles the 5-day vs 14-day evidence with recognition of steroid-unresponsive IL-17 endotypes. State when to stop at 5 days and when to pivot early to non-steroid strategies.",
        "answer": "ERS/ATS favors oral over IV corticosteroids for hospitalized exacerbations, and the REDUCE trial showed 5-day systemic courses are non-inferior to 14 days for re-exacerbations and lung-function recovery.  [oai_citation:7‡copd2.pdf](file-service://file-J3qMYmVkVT92PhaYshQrtt) In suspected steroid-unresponsive biology—flagged by an IL-17A epithelial response signature in a subset of COPD—cap exposure at 5 days, intensify short-acting bronchodilators, add antibiotics for purulence, and prioritize early rehab and discharge planning.  [oai_citation:8‡copd1.pdf](file-service://file-Jp9Dg7PFwwroaWrY9gN43h)  [oai_citation:9‡copd2.pdf](file-service://file-J3qMYmVkVT92PhaYshQrtt)"
    },
    {
        "question": "Build a cost-offset model for a payer switching 1,000 eligible patients from LABA/ICS to LAMA/LABA. Use reported U.S. costs for severe exacerbation admissions (with and without ICU) and the trial-level reductions in exacerbation rates with LAMA/LABA to estimate 12-month savings.",
        "answer": "Severe exacerbation admissions average roughly $7,000–$39,200 per event, with mechanical ventilation driving the higher end.  [oai_citation:10‡copd2.pdf](file-service://file-J3qMYmVkVT92PhaYshQrtt) Trials show LAMA/LABA reduces exacerbations versus LABA/ICS, including 11–31% relative reductions in moderate-to-severe COPD populations.  [oai_citation:11‡copd2.pdf](file-service://file-J3qMYmVkVT92PhaYshQrtt) For 1,000 patients, the product of avoided events and mean per-event cost yields six- to seven-figure annual offsets even before counting fewer pneumonia episodes associated with moving away from ICS; net savings depend on baseline event rates and local ICU mix.  [oai_citation:12‡copd2.pdf](file-service://file-J3qMYmVkVT92PhaYshQrtt)"
    },
    {
        "question": "Write a de-escalation protocol for a patient on LABA/ICS who has low eosinophils, no recent exacerbations, and recurrent pneumonia. Explain the transition to LAMA/LABA and what to monitor and when to reconsider ICS.",
        "answer": "In low-eosinophil patients without exacerbation benefit, ICS exposure adds pneumonia risk and can be withdrawn while initiating LAMA/LABA.  [oai_citation:13‡copd2.pdf](file-service://file-J3qMYmVkVT92PhaYshQrtt) Reassess at 1–4 weeks for technique/adherence and dyspnea control, and again at 12–16 weeks for events; reinstate ICS as part of triple therapy only if exacerbations recur with biomarker support.  [oai_citation:14‡copd2.pdf](file-service://file-J3qMYmVkVT92PhaYshQrtt)"
    },
    {
        "question": "Propose a PRM-guided early-intervention trial that enrolls smokers with high PRMfSAD but minimal PRMemph. Define primary endpoints and justify PRMfSAD as an enrichment biomarker.",
        "answer": "PRMfSAD maps non-emphysematous gas trapping that correlates with fewer and narrower terminal bronchioles on micro-CT and predicts faster FEV1 decline and subsequent emphysema.  [oai_citation:15‡copd1.pdf](file-service://file-Jp9Dg7PFwwroaWrY9gN43h) Randomize PRMfSAD-high, PRMemph-low participants to early LAMA/LABA versus standard timing and use FEV1 slope and time-to-first exacerbation as primary endpoints, with PRM and SGRQ as secondary outcomes.  [oai_citation:16‡copd1.pdf](file-service://file-Jp9Dg7PFwwroaWrY9gN43h)"
    },
    {
        "question": "Create a sex-aware management plan. Summarize why female smokers may decline faster and exhibit more airway wall remodeling for similar obstruction, and state how this changes imaging cadence, counseling, and therapy thresholds.",
        "answer": "Women show faster smoking-related FEV1 decline and thicker small-airway walls at matched obstruction, and severe early-onset COPD is over-represented among females, implying higher susceptibility.  [oai_citation:17‡copd1.pdf](file-service://file-Jp9Dg7PFwwroaWrY9gN43h) Mechanisms include hormonal and CYP-mediated toxicant differences and altered antioxidant responses."
    },
    {
        "question": "Create an antibiotic decision algorithm for AECOPD that starts with GOLD’s purulence trigger, overlays admission criteria (dyspnea, failure of home care, acute respiratory failure), and embeds a 48-hour reassessment. Describe when to initiate antibiotics, when to defer, when to admit, and what to verify before discharge.",
        "answer": "Initiate antibiotics when sputum becomes purulent (green/yellow) alongside worsening symptoms, since GOLD flags purulence as the practical indicator of bacterial involvement. Defer antibiotics in nonpurulent flares while intensifying bronchodilators and short systemic steroids. Admit if the patient cannot cope at home, has severe dyspnea or failure of initial therapy, or develops acute respiratory failure. At discharge, verify inhaler technique and adherence and schedule follow-ups at 1–4 and 12–16 weeks because technique errors increase ED visits and hospitalizations; these visits anchor regimen review and symptom measurement.  [oai_citation:0‡copd2.pdf](file-service://file-J3qMYmVkVT92PhaYshQrtt)  [oai_citation:1‡copd2.pdf](file-service://file-SAJgXrqrSJHP1XjicAcJP3)"
    },
    {
        "question": "Design a ‘discordant testing’ workflow for symptomatic smokers whose spirometry is borderline but PRM reveals high PRMfSAD with little PRMemph. Specify what to treat now, what to monitor, and how often to repeat spirometry and PRM to catch conversion to obstruction.",
        "answer": "PRMfSAD indicates functional small-airways disease that can precede airflow limitation and predicts faster FEV1 decline and future emphysema, whereas spirometry may remain near-normal. Begin symptom-directed therapy with dual bronchodilation (LAMA/LABA) and aggressive cessation support; PRM complements spirometry by localizing early small-airways pathology validated against micro-CT (fewer/narrower terminal bronchioles). Monitor symptoms and inhaler use in 1–4 and 12–16 weeks; repeat spirometry at routine intervals and consider annual PRM only if it will change management, since PRMfSAD is sensitive to short-term progression and correlates with GOLD stage and clinical indices (6MWD, SGRQ).  [oai_citation:2‡copd1.pdf](file-service://file-DQjD5tkQxZtJLwNTCrEuCn)  [oai_citation:3‡copd2.pdf](file-service://file-J3qMYmVkVT92PhaYshQrtt)"
    },
    {
        "question": "Propose a sex-aware follow-up cadence for women with COPD that integrates female susceptibility mechanisms (hormonal/CYP differences, thicker airway walls) with readmission-prevention timing. Specify imaging timing, initial regimen bias, and education emphasis.",
        "answer": "Female smokers show greater small-airway remodeling at matched obstruction and may be more susceptible through estrogen–CYP pathways (e.g., CYP1A1/1B1 induction and toxic metabolite formation), plus altered antioxidant responses. For women with high symptom burden or early-onset disease, consider earlier PRM to detect PRMfSAD and initiate LAMA/LABA at a lower threshold, then schedule post-exacerbation follow-ups at 1–4 and 12–16 weeks to curb the high-risk window. Emphasize inhaler technique and adherence at each visit to mitigate the increased risk of ED visits and hospitalization from handling errors.  [oai_citation:4‡copd1.pdf](file-service://file-DQjD5tkQxZtJLwNTCrEuCn)  [oai_citation:5‡copd2.pdf](file-service://file-J3qMYmVkVT92PhaYshQrtt)"
    },
    {
        "question": "Construct a pathophysiology-to-pharmacology map: connect MMP/TIMP imbalance, elastin/fibulin-5 defects, and decorin–collagen disorganization to expiratory flow limitation and justify why LAMA components are foundational before adding ICS.",
        "answer": "In COPD, inflammation increases MMPs (2/9/12), tipping MMP–TIMP balance toward elastin degradation. Fibulin-5 disruption impairs elastogenesis; decorin deficiency yields disorganized collagen. The net effect is loss of alveolar attachments and loose airway walls that collapse on expiration. Reducing cholinergic tone with a LAMA provides a pharmacologic ‘brace’ for these structurally fragile airways; ICS is reserved for biomarker-supported exacerbation biology rather than used reflexively in the absence of eosinophil signals.  [oai_citation:6‡copd1.pdf](file-service://file-DQjD5tkQxZtJLwNTCrEuCn)  [oai_citation:7‡copd2.pdf](file-service://file-J3qMYmVkVT92PhaYshQrtt)"
    },
    {
        "question": "Write a de-escalation-and-rechallenge protocol for patients on LABA/ICS with low eosinophils and recurrent pneumonia. Include the switch, the monitoring checkpoints, and the biomarker/event triggers for reintroducing ICS or moving to triple therapy.",
        "answer": "In low-eosinophil patients without exacerbation benefit, withdraw ICS to reduce pneumonia risk and transition to LAMA/LABA. Reassess at 1–4 weeks for technique/adherence and at 12–16 weeks for symptom control and events. Reintroduce ICS (as triple therapy) if exacerbations recur and eosinophils are ≥100 cells/µL or other ICS-responsive traits emerge; otherwise maintain dual bronchodilation with structured education.  [oai_citation:8‡copd2.pdf](file-service://file-SAJgXrqrSJHP1XjicAcJP3)"
    },
    {
        "question": "Create a transitional-care bundle triggered by any ICU-level AECOPD. Detail the components across two visits (1–4 and 12–16 weeks) and explain how each reduces rehospitalization risk.",
        "answer": "After ICU care, implement an intensified bundle: (1) at 1–4 weeks, verify inhaler technique, align device to patient ability, confirm adherence, and initiate/optimize maintenance (often LAMA/LABA); (2) at 12–16 weeks, reassess exacerbations and biomarkers to decide on triple therapy, roflumilast (chronic bronchitis, FEV1 <50%), or azithromycin (former smokers with low eos counts). The timing targets the 8-week high-risk period for recurrence; correcting inhaler errors and adherence reduces ED visits and severe exacerbations.  [oai_citation:9‡copd2.pdf](file-service://file-SAJgXrqrSJHP1XjicAcJP3)  [oai_citation:10‡copd2.pdf](file-service://file-SAJgXrqrSJHP1XjicAcJP3)"
    },
    {
        "question": "Design a PRM-enriched clinical study that uses PRMfSAD change over one year as a surrogate for disease modification. Describe inclusion criteria, interventions, and how PRM shifts will be interpreted alongside FEV1 and SGRQ.",
        "answer": "Include current or former smokers with high PRMfSAD and minimal PRMemph; exclude predominant emphysema to focus on early small-airways disease. Randomize to early LAMA/LABA versus usual-care timing. Over one year, interpret decreases in PRMfSAD with stabilization of FEV1 and improved SGRQ as signals of slowed small-airways decline; note that prior work shows PRMfSAD correlates with GOLD stage, 6MWD, and SGRQ and is sensitive enough for short-term follow-up.  [oai_citation:11‡copd1.pdf](file-service://file-DQjD5tkQxZtJLwNTCrEuCn)"
    },
    {
        "question": "Write a clinic SOP for deciding oral versus IV corticosteroids in hospitalized AECOPD and the minimum effective duration. Add the antibiotic rule-of-thumb and the education elements required before discharge.",
        "answer": "Prefer oral over IV corticosteroids given similar efficacy and fewer complications; limit systemic steroids to short courses (about 5 days), which were noninferior to 14-day courses for re-exacerbations and lung-function recovery. Start antibiotics when sputum purulence suggests bacterial infection, tailored to local resistance. Before discharge, teach and verify inhaler technique and adherence, since errors and poor adherence drive ED visits, hospitalizations, and mortality.  [oai_citation:12‡copd2.pdf](file-service://file-J3qMYmVkVT92PhaYshQrtt)  [oai_citation:13‡copd2.pdf](file-service://file-SAJgXrqrSJHP1XjicAcJP3)"
    },
    {
        "question": "Develop a ‘precision no-ICS’ pathway for patients with persistent symptoms but infrequent exacerbations and low eosinophils. Specify the checks you perform before stepping up any therapy and the nonpharmacologic elements that must run in parallel.",
        "answer": "For low-eosinophil, non-exacerbator patients, avoid routine ICS and optimize dual bronchodilation. Before stepping up, confirm correct device, flawless technique, and adherence, since mishandling and nonadherence are common and linked to worse outcomes. Run pulmonary rehabilitation, vaccination, and cessation support in parallel; escalate only if exacerbation biology emerges.  [oai_citation:14‡copd2.pdf](file-service://file-SAJgXrqrSJHP1XjicAcJP3)"
    },
    {
        "question": "Construct a micro-CT-to-PRM teaching page that explains, in patient-friendly language, how ‘small breathing tubes’ are lost early and why we sometimes add imaging even when basic breathing tests look okay.",
        "answer": "Micro-CT reveals that the tiniest airways (terminal/transitional bronchioles) can be reduced by 41–69% across GOLD stages and are lost even where emphysema isn’t visible. PRM combines two CT scans (in-breath/out-breath) to find air-trapping (PRMfSAD) that appears before classic obstruction and predicts faster decline and future emphysema. We sometimes add PRM to catch early disease, choose the right inhalers, and track changes over time alongside spirometry.  [oai_citation:15‡copd1.pdf](file-service://file-DQjD5tkQxZtJLwNTCrEuCn)"
    },
    {
        "question": "Compose a pharmacist-led clinic protocol for device selection and training that targets reductions in inhalation errors. Include how you will document and audit impact on exacerbations and readmissions.",
        "answer": "Pharmacists should deliver hands-on device selection and training, repeat technique checks at each 1–4 and 12–16 week visit, and troubleshoot maintenance regimens. Documentation must include standardized error checklists and adherence assessments; audits track technique error rates, adherence, and downstream severe exacerbations and readmissions, which are reduced when education is sustained.  [oai_citation:16‡copd2.pdf](file-service://file-SAJgXrqrSJHP1XjicAcJP3)"
    },
    {
        "question": "Draft a biomarker-plus-phenotype escalation note: when exacerbations persist on LAMA/LABA, how do eosinophils (≥100 vs <100 cells/µL) and phenotype (chronic bronchitis, FEV1 <50%, former smoker) steer you to triple therapy versus roflumilast or azithromycin?",
        "answer": "If exacerbations persist on LAMA/LABA and eosinophils are ≥100 cells/µL, escalate to triple therapy. If eosinophils are <100 cells/µL with chronic bronchitis and FEV1 <50%, add roflumilast; for former smokers with recurrent events and low eosinophils, consider azithromycin. Reassess technique and adherence before escalating, and continue nonpharmacologic measures.  [oai_citation:17‡copd2.pdf](file-service://file-SAJgXrqrSJHP1XjicAcJP3)"
    }
]